Explore

Trendline Trendline
Degron Therapeutics Secures $40 Million to Advance Molecular Glue Platform in Immunology

Degron Therapeutics Secures $40 Million to Advance Molecular Glue Platform in Immunology

Degron Therapeutics Secures $40 Million to Advance Molecular Glue Platform in Immunology
Trendline Trendline
Curis Reports First Quarter 2026 Financial Results Amid Ongoing Clinical Trials

Curis Reports First Quarter 2026 Financial Results Amid Ongoing Clinical Trials

Curis Reports First Quarter 2026 Financial Results Amid Ongoing Clinical Trials
Trendline Trendline
Innate Pharma Reports Progress in Immunotherapy Pipeline and Financial Results for Q1 2026

Innate Pharma Reports Progress in Immunotherapy Pipeline and Financial Results for Q1 2026

Innate Pharma Reports Progress in Immunotherapy Pipeline and Financial Results for Q1 2026
Trendline Trendline
Innate Pharma Reports Q1 2026 Business Update and Financial Results

Innate Pharma Reports Q1 2026 Business Update and Financial Results

Innate Pharma Reports Q1 2026 Business Update and Financial Results
Trendline Trendline
Innate Pharma Advances Immunotherapy Pipeline with Strategic Developments

Innate Pharma Advances Immunotherapy Pipeline with Strategic Developments

Innate Pharma Advances Immunotherapy Pipeline with Strategic Developments
Trendline Trendline
Silexion Therapeutics Initiates GMP Manufacturing for Pancreatic Cancer Drug SIL204

Silexion Therapeutics Initiates GMP Manufacturing for Pancreatic Cancer Drug SIL204

Silexion Therapeutics Initiates GMP Manufacturing for Pancreatic Cancer Drug SIL204
Trendline Trendline
MacroGenics Extends Cash Runway to 2028 Through Asset Monetization and Manufacturing Divestiture

MacroGenics Extends Cash Runway to 2028 Through Asset Monetization and Manufacturing Divestiture

MacroGenics Extends Cash Runway to 2028 Through Asset Monetization and Manufacturing Divestiture
Trendline Trendline
Lantern Pharma to Announce Q1 2026 Financial Results, Highlighting AI-Driven Oncology Developments

Lantern Pharma to Announce Q1 2026 Financial Results, Highlighting AI-Driven Oncology Developments

Lantern Pharma to Announce Q1 2026 Financial Results, Highlighting AI-Driven Oncology Developments
Trendline Trendline
Dual-Ligase Strategy Enhances Targeted Protein Degradation in Cancer Therapy

Dual-Ligase Strategy Enhances Targeted Protein Degradation in Cancer Therapy

Dual-Ligase Strategy Enhances Targeted Protein Degradation in Cancer Therapy
Trendline Trendline
Enanta Pharmaceuticals Reports Decreased Net Loss Amid Financial Results for Q2 2026

Enanta Pharmaceuticals Reports Decreased Net Loss Amid Financial Results for Q2 2026

Enanta Pharmaceuticals Reports Decreased Net Loss Amid Financial Results for Q2 2026
Trendline Trendline
Lantern Pharma to Announce Q1 2026 Financial Results Amid AI-Driven Oncology Developments

Lantern Pharma to Announce Q1 2026 Financial Results Amid AI-Driven Oncology Developments

Lantern Pharma to Announce Q1 2026 Financial Results Amid AI-Driven Oncology Developments
Trendline Trendline
Enanta Pharmaceuticals Reports Q2 2026 Financial Results Highlighting Revenue Growth and Strategic Developments

Enanta Pharmaceuticals Reports Q2 2026 Financial Results Highlighting Revenue Growth and Strategic Developments

Enanta Pharmaceuticals Reports Q2 2026 Financial Results Highlighting Revenue Growth and Strategic Developments